{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T22:53:08Z","timestamp":1784847188395,"version":"3.55.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T00:00:00Z","timestamp":1678320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004702","name":"Universit\u00e0 degli Studi di Genova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004702","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>Increased detection of prostate cancer (PCa) recurrences using [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT has been reported by adding forced diuresis or late-phase imaging to the standard protocol. However, the combination of these procedures in the clinical setting is still not standardized.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>One hundred prospectively recruited biochemical recurrent PCa patients were restaged with dual-phase [<jats:sup>68<\/jats:sup>Ga]Ga-PSMA-11 PET\/CT from September 2020 to October 2021. All patients received a standard scan (60\u00a0min), followed by diuretics (140\u00a0min) and a late-phase abdominopelvic scan (180\u00a0min). PET readers with low (<jats:italic>n<\/jats:italic>\u2009=\u20092), intermediate (<jats:italic>n<\/jats:italic>\u2009=\u20092), or high (<jats:italic>n<\/jats:italic>\u2009=\u20092) experience rated (i) standard and (ii) standard\u2009+\u2009forced diuresis late-phase images in a stepwise fashion according to E-PSMA guidelines, scoring their level of confidence. Study endpoints were (i) accuracy against a composite reference standard, (ii) reader\u2019s confidence level, and (iii) interobserver agreement.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Forced diuresis late-phase imaging increased the reader\u2019s confidence category for local and nodal restaging (both <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and the interobserver agreement in identifying nodal recurrences (from moderate to substantial, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.01). However, it significantly increased diagnostic accuracy exclusively for local uptakes rated by low-experienced readers (from 76.5 to 84%, <jats:italic>p<\/jats:italic>\u2009=\u20090.05) and for nodal uptakes rated as uncertain at standard imaging (from 68.1 to 78.5%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). In this framework, SUVmax kinetics resulted in an independent predictor of PCa recurrence compared to standard metrics, potentially guiding the dual-phase PET\/CT interpretation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The present results do not support the systematic combination of forced diuresis and late-phase imaging in the clinical setting, but allow the identification of patients-, lesions-, and reader-based scenarios that might benefit from it.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Key Points<\/jats:title>\n                <jats:p><jats:italic>\u2022 Increased detection of prostate cancer recurrences has been reported by adding diuretics administration or an additional late abdominopelvic scan to the standard [<\/jats:italic><jats:sup><jats:italic>68<\/jats:italic><\/jats:sup><jats:italic>Ga]Ga-PSMA-11 PET\/CT procedure.<\/jats:italic><\/jats:p>\n                <jats:p><jats:italic>\u2022 We verified the added value of combined forced diuresis and delayed imaging, showing that this protocol only slightly increases the diagnostic accuracy of [<\/jats:italic><jats:sup><jats:italic>68<\/jats:italic><\/jats:sup><jats:italic>Ga]Ga-PSMA-11 PET\/CT, thus not justifying its systematic use in clinics.<\/jats:italic><\/jats:p>\n                <jats:p><jats:italic>\u2022 However, it can be helpful in specific clinical scenarios, e.g., when PET\/CT is reported by low-experienced readers. Moreover, it increased the reader's confidence and the agreement among observers.<\/jats:italic><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00330-023-09516-0","type":"journal-article","created":{"date-parts":[[2023,3,9]],"date-time":"2023-03-09T13:03:07Z","timestamp":1678366987000},"page":"3343-3353","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Combined forced diuresis and late acquisition on [68Ga]Ga-PSMA-11 PET\/CT for biochemical recurrent prostate cancer: a clinical practice-oriented study"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1937-9116","authenticated-orcid":false,"given":"Matteo","family":"Bauckneht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Miceli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Signori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"Albano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene","family":"Capitanio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Piva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo","family":"Laudicella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Franchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Riondato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Chiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Marini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fornarini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Scarale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Muni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bertagna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene A.","family":"Burger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmario","family":"Sambuceti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Morbelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,9]]},"reference":[{"key":"9516_CR1","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.19.02757","volume":"38","author":"EJ Trabulsi","year":"2020","unstructured":"Trabulsi EJ, Rumble RB, Jadvar H et al (2020) Optimum imaging strategies for advanced prostate cancer: ASCO Guideline. J Clin Oncol 38:1963\u20131996","journal-title":"J Clin Oncol"},{"key":"9516_CR2","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2967\/jnumed.117.191031","volume":"58","author":"SM Schwarzenboeck","year":"2017","unstructured":"Schwarzenboeck SM, Rauscher I, Bluemel C et al (2017) PSMA ligands for PET imaging of prostate cancer. J Nucl Med 58:1545\u20131552","journal-title":"J Nucl Med"},{"key":"9516_CR3","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.euf.2021.03.012","volume":"7","author":"NM Keegan","year":"2021","unstructured":"Keegan NM, Bodei L, Morris MJ (2021) Seek and find: current prospective evidence for prostate-specific membrane antigen imaging to detect recurrent prostate cancer. Eur Urol Focus 7:267\u2013278","journal-title":"Eur Urol Focus"},{"key":"9516_CR4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/j.euf.2016.11.002","volume":"4","author":"FE von Eyben","year":"2018","unstructured":"von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G (2018) 68Ga-labeled prostate-specific membrane antigen ligand positron emission tomography\/computed tomography for prostate cancer: a systematic review and meta-analysis. Eur Urol Focus 4:686\u2013693","journal-title":"Eur Urol Focus"},{"key":"9516_CR5","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"M Perera","year":"2020","unstructured":"Perera M, Papa N, Roberts M et al (2020) Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer-updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis. Eur Urol 77:403\u2013417","journal-title":"Eur Urol"},{"key":"9516_CR6","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2967\/jnumed.117.202945","volume":"59","author":"J Calais","year":"2018","unstructured":"Calais J, Fendler WP, Eiber M et al (2018) Impact of 68Ga-PSMA-11 PET\/CT on the management of prostate cancer patients with biochemical recurrence. J Nucl Med 59:434\u2013441","journal-title":"J Nucl Med"},{"key":"9516_CR7","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1001\/jama.294.4.433","volume":"294","author":"SJ Freedland","year":"2005","unstructured":"Freedland SJ, Humphreys EB, Mangold LA et al (2005) Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294:433\u2013439","journal-title":"JAMA"},{"key":"9516_CR8","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s00259-016-3594-z","volume":"44","author":"MT Freitag","year":"2017","unstructured":"Freitag MT, Radtke JP, Afshar-Oromieh A et al (2017) Local recurrence of prostate cancer after radical prostatectomy is at risk to be missed in 68Ga-PSMA-11-PET of PET\/CT and PET\/MRI: comparison with mpMRI integrated in simultaneous PET\/MRI. Eur J Nucl Med Mol Imaging 44:776\u2013787","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR9","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.2967\/jnumed.117.190827","volume":"58","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Calais J, Allen-Auerbach M et al (2017) 68Ga-PSMA-11 PET\/CT interobserver agreement for prostate cancer assessments: an international multicenter prospective study. J Nucl Med 58:1617\u20131623","journal-title":"J Nucl Med"},{"key":"9516_CR10","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M et al (2017) 68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging 44:1014\u20131024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR11","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.2967\/jnumed.120.261866","volume":"62","author":"C Uprimny","year":"2021","unstructured":"Uprimny C, Bayerschmidt S, Kroiss AS et al (2021) Early injection of furosemide increases detection rate of local recurrence in prostate cancer patients with biochemical recurrence referred for 68Ga-PSMA-11 PET\/CT. J Nucl Med 62:1550\u20131557","journal-title":"J Nucl Med"},{"key":"9516_CR12","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1007\/s00259-020-04696-z","volume":"47","author":"L Bianchi","year":"2020","unstructured":"Bianchi L, Borghesi M, Schiavina R et al (2020) Predictive accuracy and clinical benefit of a nomogram aimed to predict 68Ga-PSMA PET\/CT positivity in patients with prostate cancer recurrence and PSA < 1 ng\/mL external validation on a single institution database. Eur J Nucl Med Mol Imaging 47:2100\u20132105","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR13","unstructured":"Bianchi L, Castellucci P, Farolfi A et al (2021) Multicenter external validation of a nomogram for predicting positive prostate-specific membrane antigen\/positron emission tomography scan in patients with prostate cancer recurrence. Eur Urol Oncol 18:S2588\u20139311(21)00217\u20130."},{"key":"9516_CR14","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci F, Oprea-Lager DE, Emmett L et al (2021) E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur J Nucl Med Mol Imaging 48:1626\u20131638","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR15","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40644-016-0072-6","volume":"16","author":"I Rauscher","year":"2016","unstructured":"Rauscher I, Maurer T, Fendler WP, Sommer WH, Schwaiger M, Eiber M (2016) (68)Ga-PSMA ligand PET\/CT in patients with prostate cancer: how we review and report. Cancer Imaging 16:14","journal-title":"Cancer Imaging"},{"key":"9516_CR16","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.clon.2007.05.002","volume":"19","author":"A Taylor","year":"2007","unstructured":"Taylor A, Rockall AG, Powell ME (2007) An atlas of the pelvic lymph node regions to aid radiotherapy target volume definition. Clin Oncol (R Coll Radiol) 19:542\u2013550","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"9516_CR17","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","volume":"25","author":"WP Fendler","year":"2019","unstructured":"Fendler WP, Weber M, Iravani A et al (2019) Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer. Clin Cancer Res 25:7448\u20137454","journal-title":"Clin Cancer Res"},{"key":"9516_CR18","doi-asserted-by":"crossref","first-page":"567","DOI":"10.2307\/2533958","volume":"53","author":"NA Obuchowski","year":"1997","unstructured":"Obuchowski NA (1997) Nonparametric analysis of clustered ROC curve data. Biometrics 53:567\u2013578","journal-title":"Biometrics"},{"key":"9516_CR19","doi-asserted-by":"crossref","first-page":"297","DOI":"10.11613\/BM.2016.034","volume":"26","author":"F Habibzadeh","year":"2016","unstructured":"Habibzadeh F, Habibzadeh P, Yadollahie M (2016) On determining the most appropriate test cutoff value: the case of tests with continuous results. Biochem Med (Zagreb) 26:297\u2013307","journal-title":"Biochem Med (Zagreb)"},{"key":"9516_CR20","first-page":"360","volume":"37","author":"AJ Viera","year":"2005","unstructured":"Viera AJ, Garrett JM (2005) Understanding interobserver agreement: the kappa statistic. Fam Med 37:360\u2013363","journal-title":"Fam Med"},{"key":"9516_CR21","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2307\/2529310","volume":"33","author":"JR Landis","year":"1977","unstructured":"Landis JR, Koch GG (1977) The measurement of observer agreement for categorical data. Biometrics 33:159\u2013174","journal-title":"Biometrics"},{"key":"9516_CR22","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/1754-9485.12625","volume":"61","author":"N Fennessy","year":"2017","unstructured":"Fennessy N, Lee J, Shin J et al (2017) Frusemide aids diagnostic interpretation of 68Ga-PSMA positron emission tomography\/CT in men with prostate cancer. J Med Imaging Radiat Oncol 61:739\u2013744","journal-title":"J Med Imaging Radiat Oncol"},{"key":"9516_CR23","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1007\/s00259-020-04846-3","volume":"48","author":"C Uprimny","year":"2021","unstructured":"Uprimny C, Bayerschmidt S, Kroiss AS et al (2021) Impact of forced diuresis with Furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68Ga]Ga-PSMA-11-PET\/CT in the evaluation of prostate cancer patients. Eur J Nucl Med Mol Imaging 48:123\u2013133","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR24","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.2967\/jnumed.120.257741","volume":"62","author":"I Alberts","year":"2021","unstructured":"Alberts I, Niklas-H\u00fcnermund J, Sachpekidis C et al (2021) Combination of forced diuresis with additional late imaging in 68Ga-PSMA-11 PET\/CT: effects on lesion visibility and radiotracer uptake. J Nucl Med 62:1252\u20131257","journal-title":"J Nucl Med"},{"key":"9516_CR25","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s00259-012-2298-2","volume":"40","author":"A Afshar-Oromieh","year":"2013","unstructured":"Afshar-Oromieh A, Malcher A, Eder M et al (2013) PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 40:486\u2013495","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR26","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1007\/s00259-018-3965-8","volume":"45","author":"A Afshar-Oromieh","year":"2018","unstructured":"Afshar-Oromieh A, Sattler LP, Steiger K et al (2018) Tracer uptake in mediastinal and paraaortal thoracic lymph nodes as a potential pitfall in image interpretation of PSMA ligand PET\/CT. Eur J Nucl Med Mol Imaging 45:1179\u20131187","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.2967\/jnumed.116.183483","volume":"58","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Sattler LP, Mier W et al (2017) The clinical impact of additional late PET\/CT imaging with 68Ga-PSMA-11 (HBED-CC) in the diagnosis of prostate cancer. J Nucl Med 58:750\u2013755","journal-title":"J Nucl Med"},{"key":"9516_CR28","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1007\/s00259-015-3251-y","volume":"43","author":"CO Sahlmann","year":"2016","unstructured":"Sahlmann CO, Meller B, Bouter C et al (2016) Biphasic 68Ga-PSMA-HBED-CC-PET\/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging 43:898\u2013905","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR29","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1007\/s00259-019-04545-8","volume":"47","author":"I Alberts","year":"2020","unstructured":"Alberts I, Sachpekidis C, Gourni E et al (2020) Dynamic patterns of [68Ga]Ga-PSMA-11 uptake in recurrent prostate cancer lesions. Eur J Nucl Med Mol Imaging 47:160\u2013167","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR30","doi-asserted-by":"crossref","first-page":"3311","DOI":"10.3390\/jcm11123311","volume":"11","author":"J Kunikowska","year":"2022","unstructured":"Kunikowska J, Pe\u0142ka K, Tayara O, Kr\u00f3licki L (2022) Ga-68-PSMA-11 PET\/CT in patients with biochemical recurrence of prostate cancer after primary treatment with curative intent-impact of delayed imaging. J Clin Med 11:3311","journal-title":"J Clin Med"},{"key":"9516_CR31","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-199018050-00004","volume":"18","author":"LL Ponto","year":"1990","unstructured":"Ponto LL, Schoenwald RD (1990) Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (Part I). Clin Pharmacokinet 18:381\u2013408","journal-title":"Clin Pharmacokinet"},{"key":"9516_CR32","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1007\/s00259-016-3419-0","volume":"43","author":"A Afshar-Oromieh","year":"2016","unstructured":"Afshar-Oromieh A, Hetzheim H, K\u00fcbler W et al (2016) Radiation dosimetry of (68)Ga-PSMA-11 (HBED-CC) and preliminary evaluation of optimal imaging timing. Eur J Nucl Med Mol Imaging 43:1611\u20131620","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR33","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1007\/s11307-018-1263-2","volume":"21","author":"M Hohberg","year":"2019","unstructured":"Hohberg M, Kobe C, T\u00e4ger P et al (2019) Combined early and late [68Ga]PSMA-HBED-CC PET scans improve lesion detectability in biochemical recurrence of prostate cancer with low psa levels. Mol Imaging Biol 21:558\u2013566","journal-title":"Mol Imaging Biol"},{"key":"9516_CR34","doi-asserted-by":"crossref","first-page":"2788","DOI":"10.3390\/cancers12102788","volume":"12","author":"MA Hoffmann","year":"2020","unstructured":"Hoffmann MA, Buchholz HG, Wieler HJ et al (2020) Dual-time point [68Ga]Ga-PSMA-11 PET\/CT hybrid imaging for staging and restaging of prostate cancer. Cancers (Basel) 12:2788","journal-title":"Cancers (Basel)"},{"key":"9516_CR35","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1007\/s00330-016-4308-4","volume":"26","author":"T Derlin","year":"2016","unstructured":"Derlin T, Weiberg D, von Klot C et al (2016) 68Ga-PSMA I&T PET\/CT for assessment of prostate cancer: evaluation of image quality after forced diuresis and delayed imaging. Eur Radiol 26:4345\u20134353","journal-title":"Eur Radiol"},{"key":"9516_CR36","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s00259-021-05616-5","volume":"49","author":"M Chavoshi","year":"2022","unstructured":"Chavoshi M, Mirshahvalad SA, Metser U, Veit-Haibach P (2022) 68Ga-PSMA PET in prostate cancer: a systematic review and meta-analysis of the observer agreement. Eur J Nucl Med Mol Imaging 49:1021\u20131029","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR37","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1007\/s00259-018-3970-y","volume":"45","author":"M Beheshti","year":"2018","unstructured":"Beheshti M, Paymani Z, Brilhante J et al (2018) Optimal time-point for 68Ga-PSMA-11 PET\/CT imaging in assessment of prostate cancer: feasibility of sterile cold-kit tracer preparation? Eur J Nucl Med Mol Imaging 45:1188\u20131196","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"9516_CR38","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13550-022-00885-z","volume":"12","author":"J Morawitz","year":"2022","unstructured":"Morawitz J, Kirchner J, Hertelendy J et al (2022) Is there a diagnostic benefit of late-phase abdomino-pelvic PET\/CT after urination as part of whole-body 68 Ga-PSMA-11 PET\/CT for restaging patients with biochemical recurrence of prostate cancer after radical prostatectomy? EJNMMI Res 12:12","journal-title":"EJNMMI Res"},{"key":"9516_CR39","first-page":"1836","volume":"36","author":"JW Keyes Jr","year":"1995","unstructured":"Keyes JW Jr (1995) SUV: standard uptake or silly useless value? J Nucl Med 36:1836\u20131839","journal-title":"J Nucl Med"},{"key":"9516_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-022-05931-5","author":"SKB Spohn","year":"2022","unstructured":"Spohn SKB, Farolfi A, Schandeler S et al (2022) The maximum standardized uptake value in patients with recurrent or persistent prostate cancer after radical prostatectomy and PSMA-PET-guided salvage radiotherapy-a multicenter retrospective analysis. Eur J Nucl Med Mol Imaging. https:\/\/doi.org\/10.1007\/s00259-022-05931-5","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"supplement 1","key":"9516_CR41","first-page":"1097","volume":"61","author":"A Pippin","year":"2020","unstructured":"Pippin A, Woolum K, Kumar K (2020) Comparison of in vitro mouse serum stability of 68Ga-labeled PSMA targeting conjugates of acyclic and macrocyclic chelators. J Nucl Med 61(supplement 1):1097","journal-title":"J Nucl Med"},{"key":"9516_CR42","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U et al (2012) 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23:688\u2013697","journal-title":"Bioconjug Chem"},{"key":"9516_CR43","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3390\/ph7070779","volume":"7","author":"M Eder","year":"2014","unstructured":"Eder M, Neels O, M\u00fcller M et al (2014) Novel preclinical and radiopharmaceutical aspects of [68Ga]Ga-PSMA-HBED-CC: a new PET tracer for imaging of prostate cancer. Pharmaceuticals (Basel) 7:779\u2013796","journal-title":"Pharmaceuticals (Basel)"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-09516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-023-09516-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-023-09516-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,21]],"date-time":"2023-04-21T12:14:18Z","timestamp":1682079258000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-023-09516-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,9]]},"references-count":43,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["9516"],"URL":"https:\/\/doi.org\/10.1007\/s00330-023-09516-0","relation":{},"ISSN":["1432-1084"],"issn-type":[{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,9]]},"assertion":[{"value":"18 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Matteo Bauckneht, MD, PhD.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Alessio Signori\u00a0has significant statistical expertise.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all patients in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The study was approved by the Ethical Committee of Regione Liguria, Italy (registration number 343\/2019).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 prospective\u2022 diagnostic or prognostic study\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}